The PTAB held in IPR2024-01312 that claims 1, 2, 4–6, 16, 17, and 19–21 of Sun Pharmaceuticals’ U.S. Patent No. However, in an ITC proceeding involving the same claims, prior art and obviousness grounds, the Commission held that the claims were not invalid. “But an initial determination at the ITC may still favor terminating a co-pending IPR proceeding,” wrote USPTO Director John Squires yesterday. Squires pointed to Sinclair Pharma Ltd. v. Hydrafacial LLC, IPR2025-00145, Paper 41 (Director Feb. 12, 2026) for support of this view. Furthermore, Squires pointed to inconsistencies in the technical findings of the Board compared with the ITC, “with inadequate explanation from the Board for the inconsistencies.”